Stockscreener 앱 받기
1.715
4.24%
0.065
전일 마감가:
$1.65
열려 있는:
$1.68
하루 거래량:
348.96K
Relative Volume:
0.33
시가총액:
$117.25M
수익:
$593.00K
순이익/손실:
$-45.85M
주가수익비율:
-2.4982
EPS:
-0.6865
순현금흐름:
$-37.97M
1주 성능:
+1.18%
1개월 성능:
-4.44%
6개월 성능:
-20.37%
1년 성능:
-43.61%
1일 변동 폭
$1.68
$1.76
1주일 범위
$1.65
$1.83
52주 변동 폭
$1.48
$4.555
Cardiff Oncology Inc Stock (CRDF) Company Profile
명칭
Cardiff Oncology Inc
전화
858-952-7570
주소
11055 FLINTKOTE AVENUE, SAN DIEGO, CA
Compare CRDF vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRDF
Cardiff Oncology Inc
|
1.715 | 112.80M | 593.00K | -45.85M | -37.97M | -0.6865 |
VRTX
Vertex Pharmaceuticals Inc
|
436.94 | 111.05B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
744.29 | 79.01B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
795.51 | 50.08B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
310.21 | 41.15B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
311.22 | 34.67B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cardiff Oncology Inc Stock (CRDF) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-05 | 개시 | Noble Capital Markets | Outperform |
| 2025-07-08 | 개시 | Ladenburg Thalmann | Buy |
| 2025-06-24 | 개시 | Jefferies | Hold |
| 2024-09-06 | 개시 | Craig Hallum | Buy |
| 2022-01-05 | 개시 | William Blair | Outperform |
| 2021-12-08 | 개시 | Robert W. Baird | Outperform |
| 2021-08-09 | 재개 | Maxim Group | Buy |
| 2020-10-22 | 개시 | H.C. Wainwright | Buy |
| 2020-10-08 | 개시 | Piper Sandler | Overweight |
모두보기
Cardiff Oncology Inc 주식(CRDF)의 최신 뉴스
Cardiff Oncology to present colorectal cancer trial data at ASCO - Investing.com
Cardiff Oncology to present colorectal cancer trial data at ASCO By Investing.com - Investing.com Canada
Cardiff Oncology to Present Updated Data on Onvansertib in RAS-Mutated Colorectal Cancer at ASCO 2026 - Quiver Quantitative
Updated metastatic colon cancer data gets ASCO oral slot - Stock Titan
Cardiff Oncology to Present Updated Phase 2 Data of - GlobeNewswire
H.C. Wainwright reiterates Cardiff Oncology stock rating at buy By Investing.com - Investing.com Canada
Cardiff Oncology (CRDF) price target decreased by 17.38% to 8.74 - MSN
Cardiff Oncology Presents Preclinical Data on its PLK1 Inhibitor Onvansertib in Combination with a HER2-Targeted ADC at the 2026 AACR Annual Meeting - Sahm
Cardiff Oncology (CRDF) Unveils Promising Preclinical Data at AA - GuruFocus
Cardiff Oncology presents preclinical data on cancer drug combo By Investing.com - Investing.com South Africa
Cardiff Oncology presents preclinical data on cancer drug combo - Investing.com
In resistant breast cancer models, Cardiff combo drove tumor regression - Stock Titan
Cardiff Oncology (CRDF) CFO discloses initial holding of 500 common shares - Stock Titan
Cardiff Oncology (NASDAQ: CRDF) CFO awarded 486,650 stock options - Stock Titan
Cardiff Oncology (CRDF) CSO granted 300,000 stock options expiring 2036 - Stock Titan
Cardiff Oncology (CRDF) CFO receives 486,650 options at $1.58 strike - Stock Titan
Cardiff Oncology appoints Mani Mohindru as CEO - MSN
Momentum Shift: Is Cardiff Oncology Inc likely to announce a buyback2026 Breakouts & Breakdowns & Smart Swing Trading Techniques - baoquankhu1.vn
Cardiff Oncology Appoints Mani Mohindru as CEO and Expands Executive Team to Advance Cancer Drug Onvansertib - Minichart
Cardiff Oncology announces key leadership appointments to strengthen executive team for next phase of growth - marketscreener.com
Cardiff Oncology Announces Key Leadership Appointments to Strengthen Executive Team for Next Phase of Growth - Bitget
Cardiff Oncology, Inc. Announces Management Appointments - marketscreener.com
Cardiff Oncology (CRDF) Appoints New Leadership Team - GuruFocus
Cardiff Oncology, Inc. Appoints Josh Muntner as Chief Financial Officer, Effective April 6, 2026 - marketscreener.com
Cardiff Oncology, Inc. Appoints Mani Mohindru as Chief Executive Officer - marketscreener.com
Cardiff Oncology appoints new CEO, CFO and COO - TipRanks
Form 8-KCurrent report - ADVFN
What is Wall Street’s view on Cardiff Onco (CRDF) Stock | Price at $1.58, Up 1.60%Stock Distribution - Cổng thông tin điện tử tỉnh Lào Cai
Cardiff Oncology: Market Dismisses Onvansertib's Potential In First-Line Colorectal Cancer - Seeking Alpha
Short Interest in Cardiff Oncology, Inc. (NASDAQ:CRDF) Declines By 9.4% - 富途牛牛
CRDF Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Cardiff Oncology Formalizes Executive Departures Amid Strategic Review - TipRanks
Cardiff Oncology Inc. (CRDF) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Cardiff Oncology director Dr. Erlander resigns - TradingView — Track All Markets
Cardiff Oncology (CRDF) CEO awarded 600,000 options at $1.62 strike - Stock Titan
[8-K] Cardiff Oncology, Inc. Reports Material Event - Stock Titan
CRDF SEC FilingsCardiff Oncology Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Jobs Data: Can Cardiff Oncology Inc reach all time highs this yearTreasury Yields & Daily Momentum Trading Reports - baoquankhu1.vn
Noble Financial Issues Optimistic Estimate for CRDF Earnings - MarketBeat
Growth Review: What is the PEG ratio of Cardiff Oncology Inc2026 Buyback Activity & Risk Controlled Daily Plans - baoquankhu1.vn
Cardiff Oncology, Inc. (NASDAQ:CRDF) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Analysts Offer Insights on Healthcare Companies: Nkarta (NKTX), QT Imaging Holdings (QTI) and Cardiff Oncology (CRDF) - The Globe and Mail
Vanguard (NASDAQ: CRDF) reports 0 shares after Jan 12, 2026 realignment - stocktitan.net
Craig-Hallum reiterates Buy on Cardiff Oncology stock, $10 target By Investing.com - Investing.com Canada
Craig-Hallum reiterates Buy on Cardiff Oncology stock, $10 target - Investing.com
William Blair reiterates Cardiff Oncology stock rating on drug data By Investing.com - ca.investing.com
H.C. Wainwright reiterates Cardiff Oncology stock rating at buy - Investing.com
Cardiff Oncology Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
CRDF: Onvansertib plus FOLFIRI+BEV achieved a 72% response rate and strong PFS in RAS mutated CRC - TradingView
Cardiff Oncology Showcases Onvansertib: 72% ORR Signal in Phase II RAS-Mutant mCRC Webinar - MarketBeat
Cardiff Oncology Inc to Host KOL Webinar Transcript - gurufocus.com
Cardiff Oncology Inc (CRDF) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Cardiff Oncology Inc 주식 (CRDF) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| PACE GARY W | Director |
Jul 30 '25 |
Buy |
2.45 |
15,000 |
36,750 |
1,345,676 |
1.23%
0.23%
자본화:
|
볼륨(24시간):